HD Insights™

Vol. 10 v.9 FINAL

Issue link: http://www.e-digitaleditions.com/i/464617

Contents of this Issue


Page 13 of 13

H D I N S I G H T S HD Insights, Vol. 10 14 Editorial Board Members Ray Dorsey, MD — Editor, University of Rochester Donald Kennedy, PhD — Stanford University Nobuyuki Nukina, MD, PhD — Riken Brain Science Institute Rodrigo Osorio — Agrupación Chilena de Huntington Bernard Ravina, MD — Voyager Therapeutics Ralf Reilmann, MD, PhD — George Huntington Institute Sarah Tabrizi, MBChB, PhD — University College London Leslie Thompson, PhD — University of California Irvine Huntington Study Group Shari Kinel, JD — HSG Executive Director Liz McCarthy, BA — HSG Director of Programs & Communications Donna Moszkowicz — HSG Event Planner Kristin Strazdins — HSG Accounting and Office Manager For more information on HD Insights, or to receive a free subscription, please visit us at www.hdinsights.org or email us at editor@hdinsights.org. Welcome to the 10th edition of HD Insights, timed for the beginning of CHDI's 10th Annual HD Therapeutics Conference. We are pleased to continue our mission to promote, disseminate and facilitate research in Huntington disease. We are grateful to the Huntington Study Group (HSG), our sponsors, and our more than 2600 subscribers for their continuing support. This edition explores several promising areas of current HD research. We discuss the positive results of Auspex Pharmaceuticals' First-HD trial, which give the HD community hope of a second FDA-approved treatment for HD. We interview Dr. Francesca Cicchetti, whose groundbreaking research was featured in the Insights of the Year competition last fall, and bring you her thoughts on advances in our current understanding of HD and the future of HD research and therapies. Dr. Lise Munsie provides a "round-up" of current basic science and clinical research in HD. Our editorial team examines the use of laquinimod in neurodegenerative disease, which has led to the ongoing LEGATO-HD Phase 2 trial, and brings you the highlights of HSG 2014. Finally, we continue to provide an up-to-date status report on ongoing and recently concluded HD clinical trials. The HD Insights team continues to rely on the support of firms dedicated to developing novel treatments to support our efforts to reach and educate the international HD research community. If you are interested in becoming a supporter, please contact me at editor@hdinsights.org. We welcome new contributors, suggestions for topics, and ideas about how we can better serve you. If you or someone you know would like to share their ideas with over 2600 HD researchers and clinicians around the world, please contact me at editor@hdinsights.org. Finally, subscription to HD Insights is always free: simply send us an email at subscribe@hdinsights.org. - - R A Y D O R S E Y , M D E D I T O R , H D I N S I G H T S T M H D D I S C L O S U R E S : D R . D O R S E Y R E C E I V E S G R A N T S U P P O R T F R O M A U S P E X P H A R M A C E U T I C A L S , T H E H U N T I N G T O N S T U D Y G R O U P , A N D P R A N A B I O T E C H N O L O G Y . E D I T O R ' S L E T T E R Copyright © Huntington Study Group 2015. All rights reserved. Contributors Meredith A. Achey, BM Ryan E. Korn, BA Lise Munsie, PhD Publication Staff Meredith A. Achey, BM — Deputy Editor Ryan E. Korn, BA — Associate Editor Robin Taylor — Production Editor Martin Holmes — Technical Editor David Kolko — Distribution Specialist H D I N S I G H T S

Articles in this issue

Links on this page

Archives of this issue

view archives of HD Insights™ - Vol. 10 v.9 FINAL